Medicsight seeks FDA 510(k) clearance to market ColonCAD software in the U.S.

Research done by scientists in Italy and Switzerland has shown that carbon nanotubes may be the ideal “smart” brain material. Their results, published December 21 in the advance online edition of the journal Nature Nanotechnology, are a promising step forward in the search to find ways to “bypass” faulty brain wiring. The research shows that

Full Post: Carbon nanotubes show promise in emerging field of neuro-engineering and neuroprosthetics

Medicsight PLC has announced the submission of a 510(k) Premarket Notification to the United States Food and Drug Administration (FDA) for clearance to market its ColonCAD(TM) image analysis software throughout the U.S.

Submission of the 510(k) notification enters Medicsight into a FDA review process. Successful clearance of the product will enable the Company to access the world’s largest healthcare market.

Medicsight has completed a large multi-reader CT Colonography clinical trial involving the review of several hundred patient datasets to support the FDA submission. This study was led by Professor Steve Halligan of University College Hospital, London, and demonstrates the significant benefits of ColonCAD technology on radiologists’ diagnostic performance.

The Company has already received regulatory approval from the necessary regulatory bodies to market ColonCAD(TM) throughout Europe, Canada, Australia, China, and Brazil. Colon CAD technology represents a breakthrough in radiology, providing a tool which can assist radiologists in the detection of colonic lesions. If detected early, colon cancer is often treatable, making Medicsight’s Colon CAD technology attractive to both patients and healthcare systems alike.

“Medicsight has assembled a strong team of leading clinical, statistical and regulatory experts to produce a 510(k) submission which we believe clearly demonstrates the safety and effectiveness of the ColonCAD product,” said David Sumner, CEO of Medicsight.

Mr. Sumner continued, “The recently reported outcomes of the U.S. National CT Colonography Trial (ACRIN 6664) demonstrating the efficacy of CT Colonography as a primary screening examination for colorectal cancer, and the inclusion of CT Colonography in the 2008 American Cancer Society guidelines for colorectal cancer screening, increasingly support the predicted growth of the U.S. CT Colonography market. With such promising market data forecasting growing demand for CT Colonography, our submission for marketing clearance for the Medicsight ColonCAD(TM) product in the U.S. is especially timely.”


New research reveals that computed tomography (CT) colonography, also known as virtual colonoscopy, has the potential to screen for two diseases at once-colorectal cancer and osteoporosis, both of which commonly affect adults over age 50. Results of the study will be presented today at the annual meeting of the Radiological Society of North America (RSNA).

Full Post: Virtual colonoscopy has potential to screen for colorectal cancer and osteoporosis at same time

The American Society for Gastrointestinal Endoscopy (ASGE) heralds the recent news of a decline in U.S. cancer deaths and incidence rates, with colorectal cancer among the top three cancers with significant declines. ASGE, representing the specialists in colorectal cancer screening, is excited by the report showing that colorectal cancer deaths among men and women dropped

Full Post: ASGE encouraged by drop in colorectal cancer deaths

Digital mammograms take longer to interpret than film-screen mammograms, according to a study performed at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. The study included four radiologists who interpreted 268 digital screening mammograms and 189 film-screening mammograms. “The average interpretation time for all of our readers was 240 seconds (4 minutes)

Full Post: Digital mammograms take longer to interpret than film-screen mammograms

A study released today in the Annals of Internal Medicine found that colonoscopy is associated with lower death rates from colorectal cancer, however, the procedure missed lesions more often on the right side of the colon versus the left side. The study highlights the importance of seeking a qualified gastrointestinal endoscopist to perform a thorough

Full Post: Study highlights importance of seeking a qualified gastrointestinal endoscopist to perform a thorough colonoscopy

Osteotech, Inc. announced today that it has initiated a pivotal clinical trial for its DuraTech BioRegeneration Matrix. The first five patients in this 60-patient trial have already been enrolled. During the study’s initial cranial surgical procedures, the patients’ dura mater (the tough, outermost membrane surrounding the brain and spinal cord) was successfully repaired by surgeons

Full Post: Osteotech starts trial for DuraTech BioRegeneration Matrix